Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 9/20 | 0.45 |
| ▸ | GRM3 | Q14832 | 6/20 | 0.45 |
| ▸ | GRM6 | O15303 | 6/20 | 0.45 |
| ▸ | GRM8 | O00222 | 4/20 | 0.45 |
| ▸ | ARG1 | P05089 | 3/20 | 0.38 |
| ▸ | ARG2 | P78540 | 2/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 6/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.36 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2788379 | 1.00 | GRM2 (0.45) | GRM2GRM3GRM6GRM8ARG1 | |
| SCHEMBL2231255 | 1.00 | GRM2 (0.45) | GRM2GRM3GRM6GRM8ARG1 | |
| SCHEMBL2231253 | 1.00 | GRM2 (0.45) | GRM2GRM3GRM6GRM8ARG1 | |
| SCHEMBL2230041 | 1.00 | GRM2 (0.45) | GRM2GRM3GRM6GRM8ARG1 | |
| SCHEMBL13319983 | 0.74 | GRM2 (0.53) | GRM2GRM3GRM6GRM8GRM1 | |
| SCHEMBL20543419 | 0.74 | GRM6 (0.41) | GRM2GRM3GRM6GRM8ARG1 | |
| SCHEMBL15062900 | 0.73 | ARG1 (0.42) | GRM2GRM3GRM6GRM8ARG1 | |
| SCHEMBL28686657 | 0.73 | ARG1 (0.42) | GRM2GRM3GRM6GRM8ARG1 | |
| SCHEMBL8438555 | 0.71 | GRM2 (0.40) | GRM2GRM3GRM6GRM8ARG1 | |
| SCHEMBL8442848 | 0.71 | GRM2 (0.40) | GRM2GRM3GRM6GRM8ARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| EP-2382975-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2377530-A2 | Modulation of neurogenesis by PDE inhibition | Braincells, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-2377531-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| US-7998971-B2 | 2-(2-oxopyrrolidin- 1 -yl)-N-(2,3 -dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)acetoamide (MKC-231) and a second active ingredient for treating central or peripheral nervous system disorders increase neurogenesis; synergistic; drug addiction, psychological disorders, transplant rejection | BRAINCELLS INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7985756-B2 | Modulation of neurogenesis by PDE inhibition | BRAINCELLS INC. (US) | 2011-07-26 | — | — | US | disclosed |
| EP-2314289-A1 | Gaba receptor mediated modulation of neurogenesis | Braincells, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
| US-20110092464-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20080108574-A1 | MELANOCORTIN RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080103105-A1 | HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103165-A1 | PPAR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080064671-A1 | COMBINATIONS CONTAINING A 4-ACYLAMINOPYRIDINE DERIVATIVE | BRAINCELLS, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-20070270449-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | GRM2 29/4885GRM3 30/4885GRM6 31/4885 |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | GABRB2, GAP43, GABRB1 | GRM2 31/4885GRM3 41/4885GRM6 45/4885 |
| US-20080108574-A1 | MELANOCORTIN RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | MC1R, MC3R, MC5R | GRM2 62/4885GRM3 47/4885GRM6 58/4885 |
| US-20080103105-A1 | HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS | HMGCR, DCX, SREBF1 | GRM2 54/4885GRM3 151/4885GRM6 104/4885 |
| US-20070270449-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR5A, HTR6, GAP43 | GRM2 69/4885GRM3 65/4885GRM6 55/4885 |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | GRM2 148/4885GRM3 259/4885GRM6 226/4885 |
| US-20080103165-A1 | PPAR MEDIATED MODULATION OF NEUROGENESIS | PPARG, PPARA, PPARD | GRM2 20/4885GRM3 27/4885GRM6 28/4885 |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | PDE2A, PDE4A, DCX | GRM2 253/4885GRM3 333/4885GRM6 246/4885 |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | GAP43, GABRB1, GABRB3 | GRM2 67/4885GRM3 74/4885GRM6 70/4885 |
| US-20110092464-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | DCX, NGF, BDNF | GRM2 121/4885GRM3 85/4885GRM6 97/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | GRM2 268/4885GRM3 110/4885GRM6 182/4885 |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | GAP43, BDNF, DCX | GRM2 44/4885GRM3 42/4885GRM6 35/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | GRM2 29/4885GRM3 30/4885GRM6 31/4885 |
| US-20080064671-A1 | COMBINATIONS CONTAINING A 4-ACYLAMINOPYRIDINE DERIVATIVE | GRIN2C, COQ8A, GRIN2D | GRM2 50/4885GRM3 194/4885GRM6 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.